Clinical application status of T cell immunoglobulin and mucin domain-containing protein 3 and its monoclonal antibody in tumor
10.7619/jcmp.20232215
- VernacularTitle:T细胞免疫球蛋白和黏蛋白结构域3及其单抗在肿瘤中的临床应用现状
- Author:
Shuyue GAO
1
;
Feiyu ZHAO
;
Runjia FAN
;
Jiamin CHENG
;
Niansong QIAN
Author Information
1. 解放军医学院,北京,100853
- Keywords:
T-cell immunoglobulin and mucin domain 3;
tumor immune microenvironment;
immune inhibitory receptor;
tumor;
prognostic biomarker;
clinical application
- From:
Journal of Clinical Medicine in Practice
2023;27(24):132-137
- CountryChina
- Language:Chinese
-
Abstract:
T cell immunoglobulin and mucin domain-containing protein 3(Tim-3)is a member of the Tim family,which is widely expressed on the surface of various cells and can be involved in the occurrence and development of diseases such as autoimmune,infection and cancer.Clinical trials have found that a combination of blocking Tim-3 and programmed cell death 1(PD-1)can improve the anti-cancer immune response and regression of tumors in patients with advanced cancer.This arti-cle reviewed the basic biological structure of Tim-3,corresponding ligand and its role in tumor micro-environment,and summarized the ongoing clinical trials of TIM-3.These data suggested that Tim-3 could be used as a potentially significant checkpoint receptor for future anti-tumor therapy,and sum-marized the ongoing clinical trials of drugs,indicating that Tim-3 can be used as a potential check-point receptor for future anti-tumor therapy.
